Ginkgo Bioworks Holdings (DNABW) Profit After Tax (2020 - 2026)
Ginkgo Bioworks Holdings (DNABW) reported Profit After Tax of -$76.1 million for Q1 2026, up 16.38% on a YoY basis from -$65.4 million in Q1 2025, and up 5.81% quarter-over-quarter from -$80.8 million in Q4 2025.
Ginkgo Bioworks Holdings (DNABW) Profit After Tax (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings has reported Profit After Tax for 7 years, with the latest figure at -$76.1 million in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax rose 16.38% year-over-year to -$76.1 million; the trailing twelve-month figure through Mar 2026 stood at -$297.9 million (up 36.9% YoY), and the FY2025 full-year result was -$312.8 million, up 42.83% from the prior year.
- Profit After Tax for Q1 2026 stood at -$76.1 million, up from -$80.8 million in the prior quarter.
- The five-year high for Profit After Tax was -$56.4 million in Q3 2024, with the low at -$670.6 million in Q2 2022.
- Historically, Profit After Tax has averaged -$231.6 million across 5 years, with a median of -$173.3 million in 2023.
- The largest YoY upside for Profit After Tax was 89.04% in 2022 against a maximum downside of 1131.22% in 2022.
- Ginkgo Bioworks Holdings' Profit After Tax stood at -$175.5 million in 2022, then slipped by 20.65% to -$211.7 million in 2023, then surged by 49.2% to -$107.5 million in 2024, then gained by 24.91% to -$80.8 million in 2025, then climbed by 5.81% to -$76.1 million in 2026.
- The last three Profit After Tax figures came in at -$76.1 million (Q1 2026), -$80.8 million (Q4 2025), and -$80.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.74 Mn |
| 10 | Ginkgo Bioworks Holdings | - | - | 16.38 Mn | -76.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -76.06 Mn |
| Dec 31, 2025 | -80.75 Mn |
| Sep 30, 2025 | -80.76 Mn |
| Jun 30, 2025 | -60.30 Mn |
| Mar 31, 2025 | -90.96 Mn |
| Dec 31, 2024 | -107.53 Mn |
| Sep 30, 2024 | -56.40 Mn |
| Jun 30, 2024 | -217.18 Mn |
| Mar 31, 2024 | -165.91 Mn |
| Dec 31, 2023 | -211.69 Mn |
| Sep 30, 2023 | -302.89 Mn |
| Jun 30, 2023 | -173.32 Mn |
| Mar 31, 2023 | -204.97 Mn |
| Dec 31, 2022 | -175.47 Mn |
| Sep 30, 2022 | -670.13 Mn |
| Jun 30, 2022 | -670.57 Mn |
| Mar 31, 2022 | -592.59 Mn |
| Dec 31, 2021 | -1.60 Bn |
| Sep 30, 2021 | -102.41 Mn |
| Jun 30, 2021 | -54.46 Mn |